open access

Vol 58, No 4 (2007)
Postgraduate education
Published online: 2007-05-17
Submitted: 2013-02-15
Get Citation

The medical treatment of acromegaly

Aart-Jan van der Lely
Endokrynologia Polska 2007;58(4):361-363.

open access

Vol 58, No 4 (2007)
Postgraduate education
Published online: 2007-05-17
Submitted: 2013-02-15

Abstract

Acromegaly can be treated with several medical modalities. The growth hormone (GH) receptor antagonist pegvisomant, in particular, is able to reduce serum insulin-like growth factor I (IGF-I) concentrations to almost any desired level. Along with this important achievement come other practical issues. The most important is that IGF-I also has metabolic actions, especially the control of serum glucose concentrations. As somatostatin analogues and pegvisomant have their own intrinsic differential effects on serum GH levels and actions as well as on serum IGF-I levels and actions, it should not automatically be assumed that absolute concentrations of these parameters of disease activity reflect the same levels of action. In the ideal situation we should be able to develop treatment of specific target levels for both GH and IGF-I that might even be patient-specific as well. To date we have not moved as far as this, but awareness of treatment-specific differential effects might help us to understand some of the signs and symptoms that we encounter in acromegalic patients.
(Pol J Endocrinol 2007; 58 (4): 361-363)

Abstract

Acromegaly can be treated with several medical modalities. The growth hormone (GH) receptor antagonist pegvisomant, in particular, is able to reduce serum insulin-like growth factor I (IGF-I) concentrations to almost any desired level. Along with this important achievement come other practical issues. The most important is that IGF-I also has metabolic actions, especially the control of serum glucose concentrations. As somatostatin analogues and pegvisomant have their own intrinsic differential effects on serum GH levels and actions as well as on serum IGF-I levels and actions, it should not automatically be assumed that absolute concentrations of these parameters of disease activity reflect the same levels of action. In the ideal situation we should be able to develop treatment of specific target levels for both GH and IGF-I that might even be patient-specific as well. To date we have not moved as far as this, but awareness of treatment-specific differential effects might help us to understand some of the signs and symptoms that we encounter in acromegalic patients.
(Pol J Endocrinol 2007; 58 (4): 361-363)
Get Citation

Keywords

acromegaly; somatostatin analogues; growth hormone receptor antagonist; glucose and insulin metabolism

About this article
Title

The medical treatment of acromegaly

Journal

Endokrynologia Polska

Issue

Vol 58, No 4 (2007)

Pages

361-363

Published online

2007-05-17

Bibliographic record

Endokrynologia Polska 2007;58(4):361-363.

Keywords

acromegaly
somatostatin analogues
growth hormone receptor antagonist
glucose and insulin metabolism

Authors

Aart-Jan van der Lely

Important: This website uses cookies.tanya dokter More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Via MedicaWydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl